Tubulin is a critical antifungal target. However, current tubulin-targeting fungicides are limited by structural simplicity and single target site mechanisms, underscoring the imperative to diversify their chemical architectures. To address this challenge, we strategically employed a scaffold-hopping approach to incorporate the imidazo[1, 2-a]pyridine scaffold─a structural analog of benzimidazole─fused with a hydrazone fragment, synthesizing a series of novel imidazo[1, 2-a]pyridine hydrazone derivatives and evaluating their antifungal activity. Among these, compound B10 exhibited an EC50 value of 1.52 μg/mL against Botryosphaeria dothidea, outperforming fenbendazole and ferimzone. At 200 μg/mL, it displayed excellent in vivo control efficacy of 63.6%. Mechanistic investigations unveiled that compound B10 formed multiple hydrogen bonds and π-π interactions with tubulin, and further induced intracellular microtubule aggregation, thereby disrupting both hyphal morphology and cellular architecture. This study provides strong evidence for structural diversification in tubulin-targeting antifungal agents, offering new perspectives for overcoming existing limitations in antifungal therapy.